Having stripped back its workforce, antibiotics biotech Spero Therapeutics continues to strip away its remaining pipeline. The latest program to be discontinued is SPR206, a next-gen polymyxin ...

Shai Biran; Investor Relations; Spero Therapeutics Inc. Esther Rajavelu; Interim President, Interim Chief Executive Officer, Chief Financial Officer, Treasurer, Chief Business Officer; Spero ...

CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for ...

Good afternoon, and welcome to the Spero Therapeutics Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time, all participants are in listen-only-mode. Following the company's ...

SperoClinic A patient works with The Spero Clinic. Suicide Disease CRPS can be triggered after a minor injury has occurred and can worsen over time to become a howling, raging storm of pure pain.

Shai Biran; Investor Relations; Spero Therapeutics Inc. Esther Rajavelu; Interim President, Interim Chief Executive Officer, Chief Financial Officer, Treasurer, Chief Business Officer; Spero ...

The FDA's decision not to approve Spero Therapeutics' oral antibiotic tebipenem Hbr for adults with complicated urinary tract infections (cUTI) further increases the threat of antibiotic ...

GSK is paying $66 million upfront to license rights to Spero Therapeutics novel antibiotic tebipenem Hbr, unswayed by the FDA's decision earlier this year not to approve the drug for adults with ...

Spero Therapeutics Inc. (NASDAQ:SPRO) stock has tumbled to a 52-week low, touching down at $0.51, representing a steep 20.7%... In a challenging year for Spero Therapeutics (NASDAQ:SPRO), the ...

Elsewhere in the pipeline is an option for complicated UTIs in Spero Therapeutics-partnered antibiotic tebipenem HBr, which is currently enrolling patients for a phase 3 study. That drug is meant ...